Novel Corona Turkish Novel Protocol

Aim: To share a novel corona treatment method that is effective on patients with the scientific community. Introduction: The new corona infection has caused a different fear all over the world, and many studies have been conducted to prolong the lives of patients who die from complications or while being treated. Materials & Methods: Among the 2000 patients who were admitted to the service(500), outpatient clinic(1420) and hospitalized in intensive care (80), 147 patients who were examined naively during the period 1.2.2021-1.4.2021 were included in the study cross-sectionally. Patients at risk of death in intensive care and pre-treatment protocols at varying rates depending on the different age. Regarding the diagnosis and treatment of the disease; Since it is known that even the effects of drugs that cause complications cause human death, it was prioritized to make the treatment plan accordingly and pay attention to the complications of these treatments. The patient, whose problems with hydroxychloroquine, favipiravir and other protocols are recovering, can lead to lung edema, intubation in the intensive care unit and subsequent death. Although the complications and mortality rate of the disease is not more than influenza, it seems possible to prevent some of the deaths. The age of patients’ distrubition 5 from 94 years old, avarage age 42 years old. drugs used in treatment planning, D vitamins single dose and zinc , tigacycline , vancomycin (renal function controlled), meropenem 1 gr (renal function controlled),enoxaparin (renal function controlled) pantoprasol , 4 gr ascorbic acid will be infused,dexamethasone , budesonide. If there is an increase in the response to antibiotherapy, ivermectine therapy, tocilisumab treatment should be added without delay. tocilisumab therapy ; tocilisumab and ivermectine treatment of patients will be consideredaccording to crp decrease. Result: The patient is treated and remains normal for three days, the patient can be discharged. There was no need for tocilizumab treatment on the patients did not use favipiravir treatment among were followed up. Longest treatment protocol is completed 21 days; shortest treatment protocol is completed 3 days. No additional complications were encountered in 800 cases treated and patient follow up completed. Discussion: While researching different treatment protocols in a new viral infection, it is a wrong practice to try new drugs rather than to cure the patients. Trying to treat patients with medications that have not been followed up and tried clearly makes more harm than normal. For this reason, it preparing protocols with known drugsare vital and not to use experimental antivirals (favipiravir, remdesivir, oseltamivir etc) that did not work in previous outbreaks.